Atnaujinkite slapukų nuostatas

Exploring Sources of Variability Related to the Clinical Translation of Regenerative Engineering Products: Proceedings of a Workshop [Minkštas viršelis]

  • Formatas: Paperback / softback, 132 pages, aukštis x plotis: 229x152 mm
  • Išleidimo metai: 19-Jul-2019
  • Leidėjas: National Academies Press
  • ISBN-10: 0309489091
  • ISBN-13: 9780309489096
Kitos knygos pagal šią temą:
  • Formatas: Paperback / softback, 132 pages, aukštis x plotis: 229x152 mm
  • Išleidimo metai: 19-Jul-2019
  • Leidėjas: National Academies Press
  • ISBN-10: 0309489091
  • ISBN-13: 9780309489096
Kitos knygos pagal šią temą:
The emerging multidisciplinary field of regenerative engineering is devoted to the repair, regeneration, and replacement of damaged tissues or organs in the body. To accomplish this it uses a combination of principles and technologies from disciplines such as advanced materials science, developmental and stem cell biology, immunology, physics, and clinical translation. The term "regenerative engineering" reflects a new understanding of the use of tissue engineering for regeneration and also the growing number of research and product development efforts that incorporate elements from a variety of fields. Because regenerative engineered therapies rely on live cells and scaffolds, there are inherent challenges in quality control arising from variability in source and final products. Furthermore, each patient recipient, tissue donor, and product application is unique, meaning that the field faces complexities in the development of safe and effective new products and therapies which are not faced by developers of more conventional therapies. Understanding the many sources of variability can help reduce this variability and ensure consistent results.



The Forum on Regenerative Medicine hosted a public workshop on October 18, 2018, in Washington, DC, to explore the various factors that must be taken into account in order to develop successful regenerative engineering products. Invited speakers and participants discussed factors and sources of variability in the development and clinical application of regenerative engineering products, characteristics of high-quality products, and how different clinical needs, models, and contexts can inform the development of a product to improve patient outcomes. This publication summarizes the presentation and discussion of the workshop.

Table of Contents



Front Matter 1 Introduction and Overview 2 Sources of Variability Associated with Regenerative Therapies: Lessons from Case Studies 3 Factors Contributing to Patient Variability 4 Addressing Variability in Donor Tissues and Cells 5 Addressing Variability and Meeting Quality Expectations in the Manufacturing Setting 6 Exploring Variability and Its Impact on Product Regulation and Outcomes 7 Potential Next Steps to Consider for Addressing Variability References Appendix A: Workshop Agenda Appendix B: Speaker Biographical Sketches Appendix C: Statement of Task Appendix D: Registered Attendees
Acronyms and Abbreviations xix
1 Introduction and Overview
1(8)
Developing Regenerative Engineering Products
3(5)
Organization of the Workshop and Proceedings
8(1)
2 Sources of Variability Associated With Regenerative Therapies: Lessons From Case Studies
9(14)
Case Study 1 Variability in the Use of Mesenchymal Stem Cells for Treating Cardiomyopathy
10(4)
Case Study 2 Sources of Variability in Preclinical and Clinical Research on Stem Cell Therapies for ALS
14(3)
Case Study 3 Variability in the Development of CAR T Cell Therapy
17(2)
Discussion
19(4)
3 Factors Contributing to Patient Variability
23(18)
Understanding Therapeutic Mechanisms
24(4)
Outcome Variability in Cardiovascular Stem Cell Trials
28(3)
Acceptable Results from Unacceptable Variability
31(5)
Allogeneic Cell Therapy for Degenerative Disc Disease
36(5)
4 Addressing Variability in Donor Tissues and Cells
41(16)
The Challenge of Variability in CAR T Cell Manufacturing
42(3)
Identifying and Processing Cells for Regenerative Therapies
45(5)
The Role of Preservation in the Variability of Regenerative Medicine Products
50(3)
Discussion
53(4)
5 Addressing Variability and Meeting Quality Expectations in the Manufacturing Setting
57(14)
Addressing Variability in Cell and Gene Therapy Manufacturing
59(2)
Using Elements of Quality by Design to Manage Variability
61(3)
Advances in Tissue Cryopreservation
64(3)
Discussion
67(4)
6 Exploring Variability and its Impact on Product Regulation and Outcomes
71(8)
VentriGel: A Case Example of a Regenerative Engineering Therapy
72(3)
Variability of Regenerative Engineering Products and the Regulatory Approval Pathway
75(4)
7 Potential Next Steps to Consider for Addressing Variability
79(10)
Crosscutting Topic Discussion
79(3)
Final Thoughts
82(3)
References
85(4)
APPENDIXES
A Workshop Agenda
89(6)
B Speaker Biographical Sketches
95(10)
C Statement of Task
105(2)
D Registered Attendees
107